GlobeNewswire

Mandalay Resources Corporation Announces Production and Sales Results for the Second Quarter of 2018

Dela

TORONTO, July 10, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) (OTCQB:MNDJF) announced today its production and sales results for the second quarter of 2018.

Mandalay produced a consolidated 22,348 saleable ounces of gold equivalent and sold 22,052 ounces of gold equivalent in the second quarter of 2018.

Dominic Duffy, President and Chief Executive Officer of Mandalay, commented, "The second quarter of 2018 was a transitional production and sales quarter for Mandalay as the Company began to transition production into the Brunswick Lode at Costerfield. Over the next two quarters we expect to see production lift at both operations due to the initiation of mining operations at Brunswick, and mining anticipated higher grades at Björkdal.  Consequently, the Company remains confident that it will reach its 2018 production guidance of 101,000 to 113,000 gold equivalent ounces."

Mr. Duffy continued, "Björkdal produced 14,017 ounces of gold in the second quarter of 2018. The Company is in the process of adding automation controls to the processing plant and we are beginning to see additional recovery improvements of approximately 1% as the circuit stabilizes. This is also expected to result in the removal of more gold in the gravity circuit, with the overall impact of improving our payables."

Mr. Duffy concluded, "Costerfield produced 8,331 gold equivalent ounces in the second quarter of 2018. Second quarter production was lower than in the previous year quarter due to a combination of expected lower mining grades and available ore in the current producing areas. The Company intercepted the Brunswick Lode during the second quarter and is currently dewatering this Lode. We expect a significant increase in production once dewatering is completed and mining initiated during the third quarter. Simultaneously, we are aggressively continuing our infill and extensional drilling program on the Youle lode."

Saleable production for the three months ended June 30, 2018:

  • The Company produced a total of 19,154 ounces gold and 503 tonnes antimony, representing a total of 22,348 ounces of gold equivalent production in the second quarter of 2018, versus 28,219 ounces gold, 765 tonnes of antimony and 359,457 ounces silver in the second quarter of 2017, representing a total of 38,491 ounces of gold equivalent. 
  • Production at Björkdal (Sweden) was 14,017 ounces gold in the second quarter of 2018, as compared to 16,112 ounces gold in the second quarter of 2017.
  • Production at Costerfield (Australia) was 5,137 ounces gold and 503 tonnes antimony in the second quarter of 2018, versus 8,933 ounces gold and 765 tonnes antimony in the second quarter of 2017. 
  • Production at Cerro Bayo (Chile) remains suspended; therefore, there was no production in the second quarter of 2018.

Table 1 - Second quarter and six month saleable production for 2018 and 2017

Metal Source Three months ended 
30 June 2018
Three months ended 
30 June 2017
Six months ended
30 June 2018
Six months ended
30 June 2017
Gold (oz) Björkdal 14,017 16,112 26,733 26,760
  Costerfield 5,137 8,933 11,724 16,920
  Cerro Bayo - 3,174 - 5,909
  Total 19,154 28,219 38,457 49,589
Antimony (t) Costerfield 503 765 1,108 1,506
Silver (oz) Cerro Bayo - 359,457 - 794,533
Average quarterly prices:          
Gold US$/oz   1,307 1,256    
Antimony US$/t   8,295 8,816    
Silver US$/oz   16.55 17.15    
Au Eq. (oz)1 Björkdal 14,017 16,112 26,733 26,760
  Costerfield 8,331 14,300 18,787 27,191
  Cerro Bayo - 8,079 - 17,021
  Total 22,348 38,491 45,520 70,972

1  Quarterly gold equivalent ounces ("Au Eq. oz") produced is calculated by multiplying the saleable quantities of gold ("Au"), silver ("Ag"), and antimony ("Sb") in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au in the period.  Average Au price in the period is calculated as the average of the daily LME PM fixes in the period, with price on weekend days and holidays taken of the last business day; average Sb price in the period is calculated as the average of the daily average of the high and low Rotterdam warehouse prices for all days in the period, with price on weekend days and holidays taken from the last business day; average Ag price in the period is calculated as the average of the daily London Broker's silver spot price for all days in the period, with price on weekend days and holidays taken from the last business day. The source for all prices is www.metalbulletin.com.

Saleable production for the six months ended June 30, 2018:

  • The Company produced a total of 38,457 ounces gold and 1,108 tonnes antimony, representing a total of 45,520 ounces of gold equivalent production, versus 49,589 ounces gold, 1,506 tonnes of antimony and 794,533 ounces silver in the corresponding six months of 2017, representing a total of 70,972 ounces of gold equivalent.
  • Production at Björkdal was 26,733 ounces gold.
  • Production at Costerfield was 11,724 ounces gold and 1,108 tonnes antimony. 
  • Production at Cerro Bayo remains suspended; therefore, there was no production in 2018.

Sales for the three months ended June 30, 2018:

  • The Company sold 18,497 ounces gold and 560 tonnes antimony, representing a total of 22,052 ounces of gold equivalent in the second quarter of 2018, versus 24,898 ounces gold, 806 tonnes antimony, and 377,916 ounces silver in the second quarter of 2017, representing a total of 35,709 ounces of gold equivalent.
  • Björkdal sold 12,428 ounces gold in the second quarter of 2018, versus 12,752 ounces gold in the second quarter of 2017.
  • Costerfield sold 6,069 ounces gold and 560 tonnes antimony in the second quarter of 2018, versus 8,912 ounces gold and 806 tonnes antimony in the second quarter of 2017.
  • Cerro Bayo had no sales in the second quarter of 2018, as production remains suspended.

Sales for the six months ended June 30, 2018:

  • The Company sold 43,305 ounces gold and 1,239 tonnes antimony, representing a total of 51,203 ounces of gold equivalent, versus 48,564 ounces gold, 1,514 tonnes antimony, and 829,693 ounces silver in the second quarter of 2017, representing a total of 70,510 ounces of gold equivalent.
  • Björkdal sold 30,105 ounces gold.
  • Costerfield sold 13,200 ounces gold and 1,239 tonnes antimony.
  • Cerro Bayo had no sales during 2018, as production remains suspended.

Table 2 - Second quarter and six month sales for 2018 and 2017

Metal Source Three months ended 
30 June 2018
Three months ended 
30 June 2017
Six months ended
30 June 2018
Six months ended
30 June 2017
Gold (oz) Björkdal 12,428 12,752 30,105 25,873
  Costerfield 6,069 8,912 13,200 16,459
  Cerro Bayo - 3,232 - 6,232
  Total 18,497 24,896 43,305 48,564
Antimony (t) Costerfield 560 806 1,239 1,514
Silver (oz) Cerro Bayo - 377,916 - 829,693
Average quarterly prices:          
Gold US$/oz   1,307 1,256    
Antimony US$/t   8,295 8,816    
Silver US$/oz   16.55 17.15    
Au Eq. (oz)1 Björkdal 12,428 12,752 30,105 25,873
  Costerfield 9,624 14,568 21,098 26,803
  Cerro Bayo - 8,389 - 17,834
  Total 22,052 35,709 51,203 70,150

1 Quarterly Au Eq. oz sold is calculated by multiplying the saleable quantities of Au, Ag, and Sb in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au for the period. The source for all prices is www.metalbulletin.com with price on weekend days and holidays taken of the last business day.

For Further Information:

Dominic Duffy
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 
647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia, Sweden and producing and exploration projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in-production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2018 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum